Table 2.
Clinical and demographic characteristics of patients included in the cost analysis
| Characteristics | Breast Surgery and BSO | ||
|---|---|---|---|
| Coordinated (N=321) n (%) |
Staged (N=2542) n (%) |
P-value | |
| Age category | 0.46 | ||
| 18 - 45 | 143 (44.6%) | 1049 (41.3%) | |
| 46 - 55 | 130 (40.5%) | 1060 (41.7%) | |
| >55 | 48 (15.0%) | 433 (17.0%) | |
| Breast Cancer | 0.03 | ||
| Yes | 312 (97.2%) | 2514 (98.9%) | |
| No | 9 (2.8%) | 28 (1.1%) | |
| Region | 0.30 | ||
| Northeast | 59 (18.4%) | 592 (23.3%) | |
| North-central | 85 (26.5%) | 583 (22.9%) | |
| South | 116 (36.1%) | 918 (36.1%) | |
| West | 53 (16.5%) | 395 (15.5%) | |
| Unknown | 8 (2.5%) | 54 (2.1%) | |
| Elixhauser Comorbidity Index | 0.24 | ||
| 0 – 3 | 235 (73.2%) | 1939 (76.3%) | |
| > 3 | 86 (26.8%) | 603 (23.7%) | |
| Year | 0.62 | ||
| 2010 | 79 (24.6%) | 622 (24.5%) | |
| 2011 | 80 (24.9%) | 676 (26.6%) | |
| 2012 | 89 (27.7%) | 624 (24.6%) | |
| 2013 | 73 (22.7%) | 620 (24.4%) | |
| Breast Surgery | <0.01 | ||
| Lumpectomy | 62 (19.3%) | 861 (33.9%) | |
| Mastectomy | 259 (80.7%) | 1681 (66.1%) | |
| Reconstruction | <0.01 | ||
| None | 106 (33.0%) | 1162 (45.7%) | |
| Post-Lumpectomy Breast Reconstruction | 15 (4.7%) | 125 (4.9%) | |
| Immediate Implant Placement | 24 (7.5%) | 170 (6.7%) | |
| Delayed Implant Placement | 153 (47.7%) | 914 (36.0%) | |
| Autologous Tissue-Based | 19 (5.9%) | 144 (5.7%) | |
| Unspecified Reconstruction | 4 (1.3%) | 27 (1.1%) | |
| BSO Surgical Approach | 1.00 | ||
| Laparoscopic | 255 (79.4%) | 2019 (79.4%) | |
| Open | 66 (20.6%) | 523 (20.6%) | |
| Concurrent Hysterectomy | <0.01 | ||
| Yes | 105 (32.7%) | 1334 (52.5%) | |
| No | 216 (67.3%) | 1208 (47.5%) | |
| Axillary Lymph Node Dissection | 0.53 | ||
| Yes | 115 (35.8%) | 863 (34.0%) | |
| No | 206 (64.2%) | 1679 (66.1%) | |
| Neoadjuvant Chemotherapy | <0.01 | ||
| Yes | 85 (26.5%) | 383 (15.1%) | |
| No | 236 (73.5%) | 2159 (84.9%) | |
| Adjuvant Chemotherapy | 1.00 | ||
| Yes | 116 (36.1%) | 917 (36.1%) | |
| No | 205 (63.9%) | 1625 (63.9%) | |
| Adjuvant Endocrine Therapy | 0.30 | ||
| Yes | 38 (11.8%) | 357 (14.0%) | |
| No | 283 (88.2%) | 2185 (86.0%) | |